US FDA has granted clearance of DaylightRx for generalized anxiety disorder
-
learn more here.
Our Solutions
Comprehensive Solution
SleepioRx
DaylightRx
Sleepio
Daylight
Spark Direct
Who We Serve
Employers
Health Plans
Benefits Consultants
Our Results
Our Research
Patient Stories
Resources
Reports
Tools
Webinars
Blog
Who We Are
About Us
Careers
News
Contact Us
Get started
US
UK
Latest news
September 4, 2024
/
News
US FDA Grants Clearance for DaylightRx
US FDA Grants Clearance for SleepioRx
August 8, 2024
/
News
Study Finds Spark Direct Effective in Improving Mood Among Adults With Depression
May 23, 2024
/
News
Running the Next Leg
April 2, 2024
/
News
The mental health system of the future, delivered today
January 2, 2024
/
News
All News
Digital therapeutics: at an inflection point
Five questions with Big Health CEO Arun Gupta
April 24, 2023
/
News
For many with mental health conditions, medication is the only option. That has to change.
Let’s bring clinically proven, non-drug digital treatments front and center to help millions in need.
January 26, 2023
/
News
Big Health Builds Out Its Leadership Team with the Appointment of Five Key Executives
Company ramps up next phase of growth in 2023 after record breaking year
January 10, 2023
/
News
Big Health Digital Therapeutics Daylight and Sleepio Selected for Evernorth Digital Health Formulary
The addition of Daylight for anxiety and Sleepio for insomnia expands access to evidence-based digital cognitive behavioral therapy to thousands of Americans
September 15, 2022
/
News
Evolving Our Leadership At Big Health
August 17, 2022
/
News
First-of-its-kind partnership provides free access to digital mental health treatments for all newly diagnosed cancer patients in the United Kingdom
July 25, 2022
/
News
Previous
Load More
Let's talk
For all media-related queries, please get in touch with us.
press@bighealth.com
Who we are
Learn about our mission, leadership, advisors, and investors.
About us